Specialty Pharmacy

Cyclin-dependent kinase inhibitor reduces Ki67 expression and shows promise in breast cancer treatment.

HIV infection continues to rise in across European countries.

Top news of the day from across the health care landscape.

When treatment with DMARDs does not work, biologic agents are used to treat RA.

Lack of adherence to HIV medications can create resistance since the virus mutates quickly.

Risankizumab achieved higher rates of clinical response in patients with Crohn’s disease.

Pennsylvania health department recommends that patients be screened for HIV, and hepatitis B and C viruses.

FDA grants accelerated approval for rucaparib (Rubraca) to treat advanced ovarian cancer.

Pembrolizumab was associated with clinically meaningful improvements in quality of life over chemotherapy.

Anti-inflammatory drugs suppress PGE2 production and leads to adverse events from peripheral blood hematopoietic stem cell harvesting.

Integrase inhibitors can reduce the HIV viral load to decrease transmission of the disease.

Wayne Grau, vice president of Legislative Affairs at Managed Health Care Associates, discusses how specialty stakeholders can take steps to improve the perception surrounding specialty pharmacies following recent drug cost controversies.

Top news of the day from across the health care landscape.

ICER seeks comment on the effectiveness and value of disease modifying therapies for relapsing remitting and primary progressive multiple sclerosis.

Global HIV incidence rates drop in some African countries.

Top news of the week in oncology and cancer drug development.

Rates of suicide elevated in cancer survivors diagnosed before the age of 25 years.

Jury declares Merck’s acquired HCV drug patent valid.

The biosimilar epoetin was well-tolerated in elderly cancer patient populations.

FDA-approved drug could reduce the risk of death in adults with diabetes and cardiovascular disease.

Top news of the day from across the health care landscape.

Top articles of the week on Specialty Pharmacy Times.

Ceritinib (Zykadia) could potentially be used as a first-line treatment in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer.

Prior research suggested that T cells become pathogenic when they encounter specific dendritic cells in the lymph nodes.

The recommended time to begin antiretroviral therapy has changed since it first arrived in the mid 90s for HIV.

Study cautions against unintended consequences of “shock and kill” treatment for HIV.

New findings may lead to therapeutic options for stopping lung cancer cells from spreading to different parts of the body.

Top news of the day from across the health care landscape.

Sofosbuvir/ribavirin treatment is typically prescribed for 12 weeks, but for some patients with hepatitis C virus, a longer duration may be needed.

Crisaborole ointment (Eucrisa) treats mild to moderate eczema in patients 2 years and older.